{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:08:27Z","timestamp":1791295707853,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.mayocp.2015.05.014","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T06:15:22Z","timestamp":1441088122000},"page":"1283-1293","source":"Crossref","is-referenced-by-count":40,"title":["Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice"],"prefix":"10.1016","volume":"90","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2015.05.014_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? a systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.2830470205","article-title":"Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989","volume":"47","author":"Ania","year":"1994","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.mayocp.2015.05.014_bib4","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.05.014_bib5","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.mayocp.2015.05.014_bib6","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2015.05.014_bib7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.mayocp.2015.05.014_bib8","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Bros\u00e9us","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.05.014_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ajh.22058","article-title":"Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis","volume":"86","author":"Pardanani","year":"2011","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.mayocp.2015.05.014_bib10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2015.05.014_bib11","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.mayocp.2015.05.014_bib12","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.mayocp.2015.05.014_bib13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.05.014_bib14","unstructured":"Swerdlow SH, Campo E, Harris NL, et\u00a0al, eds; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer;\u00a02008."},{"issue":"8","key":"10.1016\/j.mayocp.2015.05.014_bib15","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.05.014_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2015.05.014_bib17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/leu.2009.54","article-title":"The complete evaluation of erythrocytosis: congenital and acquired","volume":"23","author":"Patnaik","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.mayocp.2015.05.014_bib18","first-page":"406","article-title":"Serum erythropoietin in the diagnosis of polycythemia vera: a follow-up study","volume":"82","author":"Remacha","year":"1997","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.mayocp.2015.05.014_bib19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1309\/6BQ5K8LHVYAKUAF4","article-title":"The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia","volume":"130","author":"Gianelli","year":"2008","journal-title":"Am J Clin Path"},{"issue":"6","key":"10.1016\/j.mayocp.2015.05.014_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.23617","article-title":"Masked polycythemia vera diagnosed according to WHO and BCSH classification","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.mayocp.2015.05.014_bib23","first-page":"415","article-title":"Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes","volume":"4","author":"Rose","year":"2012","journal-title":"J\u00a0Clin Med Res"},{"issue":"4","key":"10.1016\/j.mayocp.2015.05.014_bib24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.V92.4.1091","article-title":"Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene","volume":"92","author":"Kondo","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia","volume":"18","author":"Wiestner","year":"1998","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2141.2000.02169.x","article-title":"Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia","volume":"110","author":"Wiestner","year":"2000","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2141.1999.01710.x","article-title":"Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene","volume":"107","author":"Ghilardi","year":"1999","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.05.014_bib28","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/ard.2008.097030","article-title":"Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition","volume":"68","author":"Olivieri","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mayocp.2015.05.014_bib30","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.mayocp.2015.05.014_bib31","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2011.061432","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Thiele","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.mayocp.2015.05.014_bib32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4111\/kju.2011.52.2.104","article-title":"Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma","volume":"52","author":"Cho","year":"2011","journal-title":"Korean J Urol"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.mayocp.2015.05.014_bib35","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.mayocp.2015.05.014_bib36","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.mayocp.2015.05.014_bib37","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2015.05.014_bib38","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mayocp.2015.05.014_bib40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.0954-6820.1962.tb07186.x","article-title":"Complications and causes of death in polycythaemia vera","volume":"172","author":"Chievitz","year":"1962","journal-title":"Acta Med Scand"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib43","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"issue":"17","key":"10.1016\/j.mayocp.2015.05.014_bib44","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"29","key":"10.1016\/j.mayocp.2015.05.014_bib45","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2015.05.014_bib47","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.05.014_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2015.05.014_bib49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2015.05.014_bib50","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.05.014_bib51","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.3324\/haematol.2013.087742","article-title":"JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug","volume":"98","author":"Kuriakose","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.mayocp.2015.05.014_bib52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2015.05.014_bib53","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","article-title":"Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.mayocp.2015.05.014_bib54","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.05.014_bib55","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2015.05.014_bib56","doi-asserted-by":"crossref","unstructured":"Tefferi A, Barbui T. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera [published online ahead of print April 15, 2015]. Am J Hematol. doi:10.1002\/ajh.24037.","DOI":"10.1002\/ajh.24037"},{"issue":"8","key":"10.1016\/j.mayocp.2015.05.014_bib57","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.05.014_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2011.09.017","article-title":"Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia","volume":"129","author":"Dillinger","year":"2012","journal-title":"Thromb Res"},{"issue":"15","key":"10.1016\/j.mayocp.2015.05.014_bib59","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2015.05.014_bib60","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.mayocp.2015.05.014_bib61","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2015.05.014_bib62","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2362.2010.02334.x","article-title":"Polycythemia vera-associated pruritus and its management","volume":"40","author":"Saini","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"10.1016\/j.mayocp.2015.05.014_bib63","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ajh.21508","article-title":"Essential thrombocythemia and pregnancy: observations from recent studies and management recommendations","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am J Hematol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615004656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615004656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T16:52:57Z","timestamp":1599497577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619615004656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0025619615004656"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.05.014","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}